Mural Oncology plc

Hey everyone, let's break down what's going on with Mural Oncology plc in a way that makes sense, without all the confusing finance talk. Think of this as me explaining it to you over a cup of coffee.

---

1. What happened? (The Big News, Plain and Simple)

So, here's the scoop: Mural Oncology plc has been acquired by XOMA Royalty Corporation, through its subsidiary XRA 5 Corp.

Basically, it means Mural Oncology is no longer an independent public company; it's now part of XOMA Royalty. If you owned shares, you're getting cash for them.

2. When did it happen?

This all officially went down on December 5, 2025, when the final court order for the acquisition was delivered to the Registrar of Companies in Dublin, Ireland, making the deal effective.

The Irish High Court had sanctioned the scheme on December 3, 2025. Before that, Mural's shareholders approved the deal at meetings held on October 24, 2025. The initial agreement to acquire Mural Oncology was first announced on August 20, 2025.

3. Why did it happen? (The Backstory)

To understand why this is a big deal, you need a little background. Mural Oncology entered into a "Transaction Agreement" with XOMA Royalty Corporation to be acquired. This is a strategic move for both companies. For Mural, it provides a clear exit for its shareholders, who receive a cash payout. For XOMA Royalty, it means they gain Mural's assets, potential drug pipeline, or expertise, expanding their own portfolio.

This event is a direct result of Mural Oncology's decision to sell the company to XOMA Royalty, a process that involved shareholder approval and a court-sanctioned scheme of arrangement in Ireland. They were trying to provide value to their shareholders through a cash acquisition and integrate their operations into a larger entity.

4. Why does this matter? (The "So What?")

Okay, so why is this a big deal?

• This is good news (an acquisition): This is important because Mural Oncology shareholders will receive a specific cash payment for each share they own, and the company will cease to exist as a standalone publicly traded entity. It means a definitive outcome for the company's future, with its operations now falling under XOMA Royalty.

5. Who is affected?

So, who's going to feel this? Pretty much everyone connected to Mural Oncology, but in different ways:

• Patients: The filing doesn't specify the direct impact on patients. However, the future of Mural's drug development pipeline will now be determined by XOMA Royalty, which could lead to changes in priorities or accelerated development for certain treatments.
• Employees: Employees of Mural Oncology will now be part of XOMA Royalty Corporation. This could mean new opportunities, but also potential changes in roles or company culture as the integration happens.
• Investors (that's you!): If you held Mural Oncology shares, you will receive $2.035 in cash for each Ordinary Share you owned. The company's stock will no longer trade on The Nasdaq Global Market. This is the final payout for your investment in Mural Oncology.
• The Company Itself: Mural Oncology plc is no longer an independent entity. It is now a wholly-owned subsidiary of XOMA Royalty Corporation, and its operations will be integrated into the acquiring company.

6. What happens next? (Looking Ahead)

What's on the horizon?

• Immediately: Mural Oncology's shares will be delisted from The Nasdaq Global Market. Shareholders who held shares as of 11:59 p.m. Irish local time on December 4, 2025, will receive their cash payment of $2.035 per share. Options and restricted stock units (RSUs) were also converted into cash based on the acquisition price.
• In the near future: XOMA Royalty will begin the process of fully integrating Mural Oncology's operations, assets, and personnel into its existing structure.
• Longer term: This event means the end of Mural Oncology as a standalone public company. Its legacy and future potential will now be carried forward under the umbrella of XOMA Royalty Corporation.

7. What should investors/traders know? (Your Takeaways)

If you're thinking about Mural Oncology's stock, here's what you should keep in mind:

• No More Trading: Mural Oncology's stock (MURA) will no longer be traded on the Nasdaq. The company is now private under XOMA Royalty.
• Cash Payout: If you owned shares, you are entitled to receive $2.035 in cash for each share. This is the final return on your investment in Mural Oncology.
• Finality: This acquisition marks the definitive end of Mural Oncology as a publicly traded investment opportunity.
• Biotech Exits: This kind of event is common in the biotech world, where smaller companies are often acquired by larger ones, providing an exit for early investors and a path for promising drugs or technologies to reach market.

Remember, this is just a breakdown to help you understand. Always do your own homework before making any investment decisions!